BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
About this item
Full title
Author / Creator
Publisher
New Zealand: Dove Medical Press Limited
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Dove Medical Press Limited
Subjects
More information
Scope and Contents
Contents
BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. More recently, the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown improved progression-free survival, compared to dabrafenib monotherapy, in a...
Alternative Titles
Full title
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4303458
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4303458
Other Identifiers
ISSN
1178-6930
E-ISSN
1178-6930
DOI
10.2147/OTT.S39096
